Drug Profile
Balcinrenone - AstraZeneca
Alternative Names: AZD-9977Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Acetamides; Benzoxazines; Cardiovascular therapies; Fluorinated hydrocarbons; Small molecules; Urologics
- Mechanism of Action Mineralocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure; Kidney disorders
- Discontinued Cardiovascular disorders; Diabetic nephropathies
Most Recent Events
- 05 Apr 2024 AstraZeneca plans the phase IIb MIRO-CKD trial for Renal failure and Proteinuria (Combination therapy) in the US, Austria, Bulgaria, Canada, Italy, Malaysia, Poland, Spain and Taiwan (PO) (NCT06350123)
- 19 Mar 2024 AstraZeneca plans a phase III trial in Chronic heart failure (Combination therapy) in USA, Argentina, Australia, Austria, Canada, Chile, China, Colombia, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Kores, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, Vietnam (NCT06307652)
- 22 Sep 2023 AstraZeneca completes the phase II MIRACLE trial in Chronic heart failure (Combination therapy, In adults, In the elderly) in Hungary, Belgium, Bulgaria, Canada, Czech Republic, Denmark, Germany, Italy, Japan, Lithuania, Poland, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine (NCT04595370)